VFA
ANTX icon

Valeo Financial Advisors’s AN2 Therapeutics ANTX Stock Holding History

Valeo Financial Advisors’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,446
Closed -$11.9K – 766
2025
Q4 		$11.9K Buy
+10,446
New +$12.2K ﹤0.01% 831

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Valeo Financial Advisors's ANTX Position: Q1 2026 in Review

Valeo Financial Advisors sold out of AN2 Therapeutics (ANTX) in Q1 2026, closing a stake of 10,446 shares — an estimated $11.9K sold.

Valeo Financial Advisors first reported a position in ANTX in Q4 2025 and held it in 1 quarter. The position peaked at $11.9K in Q4 2025. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Valeo Financial Advisors reported no remaining AN2 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Valeo Financial Advisors sold 10,446 AN2 Therapeutics shares in Q1 2026, an estimated $11.9K.
  • Valeo Financial Advisors first reported a position in AN2 Therapeutics in Q4 2025 and held it in 1 quarter.
  • Valeo Financial Advisors's AN2 Therapeutics position peaked at $11.9K in Q4 2025.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Valeo Financial Advisors's 13F filing for Q1 2026, filed 8 May 2026.